These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14976270)

  • 21. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
    Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure.
    Yildirir A; Sade E; Tokgozoglu L; Oto A
    Eur J Heart Fail; 2001 Dec; 3(6):717-21. PubMed ID: 11738224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).
    Volterrani M; Cice G; Caminiti G; Vitale C; D'Isa S; Perrone Filardi P; Acquistapace F; Marazzi G; Fini M; Rosano GM
    Int J Cardiol; 2011 Sep; 151(2):218-24. PubMed ID: 21764469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
    Azevedo ER; Kubo T; Mak S; Al-Hesayen A; Schofield A; Allan R; Kelly S; Newton GE; Floras JS; Parker JD
    Circulation; 2001 Oct; 104(18):2194-9. PubMed ID: 11684630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry.
    Abraham WT; Massie BM; Lukas MA; Lottes SR; Nelson JJ; Fowler MB; Greenberg B; Gilbert EM; Franciosa JA;
    Congest Heart Fail; 2007; 13(1):16-21. PubMed ID: 17268206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
    Magrì D; Palermo P; Cauti FM; Contini M; Farina S; Cattadori G; Apostolo A; Salvioni E; Magini A; Vignati C; Alimento M; Sciomer S; Bussotti M; Agostoni P
    Cardiovasc Ther; 2012 Apr; 30(2):100-8. PubMed ID: 20553283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study.
    Macdonald PS; Hill J; Krum H;
    Am J Cardiovasc Drugs; 2006; 6(6):401-5. PubMed ID: 17192130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
    DasGupta P; Lahiri A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction?
    Huang RL; Listerman J; Goring J; Giesberg C; Nading MA; Butler J
    Congest Heart Fail; 2006; 12(4):206-10; quiz 211-2. PubMed ID: 16894279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
    Spaeder J; Najjar SS; Gerstenblith G; Hefter G; Kern L; Palmer JG; Gottlieb SH; Kasper EK
    Am Heart J; 2006 Apr; 151(4):844.e1-10. PubMed ID: 16569544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A fairer comparison between carvedilol and metoprolol is still to be done].
    Johnsson G; Aberg J
    Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol.
    Triposkiadis F; Dalampiras P; Kelepeshis G; Skoularigis J; Sitafidis G
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):136-9. PubMed ID: 18397684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prospective evaluation of effect of carvedilol therapy on heart rate variability in patients with dilated cardiomyopathy].
    Hoffmann J; Grimm W; Menz V; Hufnagel G; Maisch B
    Z Kardiol; 1999 Sep; 88(9):653-60. PubMed ID: 10525927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
    Düngen HD; Apostolovic S; Inkrot S; Tahirovic E; Töpper A; Mehrhof F; Prettin C; Putnikovic B; Neskovic AN; Krotin M; Sakac D; Lainscak M; Edelmann F; Wachter R; Rau T; Eschenhagen T; Doehner W; Anker SD; Waagstein F; Herrmann-Lingen C; Gelbrich G; Dietz R;
    Eur J Heart Fail; 2011 Jun; 13(6):670-80. PubMed ID: 21429992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
    Bullinga JR; Alharethi R; Schram MS; Bristow MR; Gilbert EM
    J Card Fail; 2005 Dec; 11(9):693-9. PubMed ID: 16360965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differing beta-blocking effects of carvedilol and metoprolol.
    Stoschitzky K; Koshucharova G; Zweiker R; Maier R; Watzinger N; Fruhwald FM; Klein W
    Eur J Heart Fail; 2001 Jun; 3(3):343-9. PubMed ID: 11378006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
    Lindenfeld J; Lowes BD; Bristow MR
    Ann Pharmacother; 1999 Dec; 33(12):1266-9. PubMed ID: 10630826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
    Rouleau JL; Roecker EB; Tendera M; Mohacsi P; Krum H; Katus HA; Fowler MB; Coats AJ; Castaigne A; Scherhag A; Holcslaw TL; Packer M;
    J Am Coll Cardiol; 2004 Apr; 43(8):1423-9. PubMed ID: 15093878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.